Trupti Lingaraj

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

Elayne Chan-Penebre, Kristy G. Kuplast, Christina R. Majer et al. · Nature Chemical Biology · 2015 · 546 citations

Medicine, Medicinal Chemistry, Pharmacology +8

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

James E. Brownell, Michael D. Sintchak, James M. Gavin et al. · Molecular Cell · 2010 · 461 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones et al. · The Lancet Oncology · 2020 · 406 citations

Medicine, Cancer Biology, Oncology +12

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

Medicine, Oncology, Pharmacology +7

Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound

Lorna H. Mitchell, Allison E. Drew, Scott Ribich et al. · ACS Medicinal Chemistry Letters · 2015 · 136 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11